Close filter

Joanne Yun

Kontakt

+1 415 963 8530

Kontakt

Based in San Francisco & Palo Alto, Joanne is a member of Egon Zehnder’s Global Health Practice. In addition to her board and commercial work for global pharmaceutical and biotechnology companies, Joanne co-leads the Global Healthcare Research & Development segment of the Health Practice and has a particular focus in the oncology sector.

Prior to joining Egon Zehnder, Joanne served as a Director in the Global Oncology Business Unit for Bayer HealthCare Pharmaceuticals with responsibility for oncology-program management and new product planning. She advised on all aspects of research, development, and commercial strategy, including portfolio prioritization, business development, alliance governance, and merger integration. Joanne started her career with Bayer AG in Germany as a Bench Chemist and Laboratory Head in the Organic Synthesis Department. She later transitioned into the Corporate R&D Planning Department and was promoted to a Manager in the Strategic Planning Department, where she focused on global merger and acquisition strategies and transactions. Joanne subsequently transferred to Bayer Corporation in Connecticut, where she was a Senior Manager in Bayer Healthcare’s North America Business Development & Licensing group.

Joanne earned a BA in chemistry and French from Amherst College and a PhD in chemistry from the Massachusetts Institute of Technology. She was a National Institutes of Health/National Cancer Institute Postdoctoral Fellow at The Scripps Research Institute. Joanne is a member of the American Chemical Society, American Society of Clinical Oncology, American Society of Hematology, and Society for Immunotherapy of Cancer.

Meine Schwerpunkte

Kontakt
E-Mail an Joanne Yun
Alles durchsuchen
Interviews, Artikel und Studien
Changing language
Close icon

You are switching to an alternate language version of the Egon Zehnder website. The page you are currently on does not have a translated version. If you continue, you will be taken to the alternate language home page.

Continue to the website

Back to top